热门资讯> 正文
诺和诺德将面临股东诉讼，指控CagriSema审判欺诈
2026-07-29 02:08
- A New Jersey federal court judge on Tuesday said that Novo Nordisk (NVO) must face part of a shareholder lawsuit that accuses the Danish drugmaker of changing protocols in a key trial for its experimental type 2 diabetes and weight loss treatment CagriSema (cagrilintide/semaglutide).
- Plaintiffs say that the value of their Novo shares precipitously dropped after the discovery that protocols for the REDEFINE 1 trial were changed to permit participants to choose their dosages, Reuters reported.
- Judge Robert Kirsch, however, dismissed claims centering on alleged misleading statements and omissions.
- In February, Novo was dealt a blow after results from the REDEFINE 4 trial showed that a 15 mg dose of Eli Lilly's (LLY) tirzepatide (marketed as Zepbound) led to greater weight loss than CagriSema over 84 weeks.
More on Novo Nordisk
- Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy
- Novo Nordisk Remains A Generational Buying Opportunity Ahead Of Q2 Earnings
- Novo Nordisk: Initiating Buy, Calling The Bottom
- Novo Nordisk actively seeking deals to expand pipeline, CEO says
- Novo Nordisk says oral Wegovy success to soften sales decline
推荐文章
美股前瞻 | 今晚凌晨两点！贝森特公布对伊”史诗级金融攻势“；拼多多绩后涨逾4%！此前一度跌近5%；存储、光通信盘前齐跌
一图看懂 | 拼多多Q2营收增约8%！经调整净利略超市场预期，研发投入同比大增40%
一图看懂 | 小鹏集团Q2毛利率20.7%超预期！旗下机器人子公司完成9亿美元融资，将正式布局人形机器人赛道
美股盘前 | 存储概念普跌，闪迪跌超4%；阿里巴巴跌超3.5%，宣布800亿港元港股配售；
美扩大国债回购难抑收益率 比特币黄金应声大涨
阿里巴巴融资800亿股价大跌，市场热议港股“二次探底”
阿里重挫10%拖累恒科！港股史上最大配售落地，800亿港元全押AI遭“大空头”开炮，主权基金却逆势抢筹？
沃什若未提供明确指引 美国长债恐遭进一步抛售
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
